Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology

Long-Term Monitoring and Survivorship

At a Glance

Long-term follow-up for CFH deficiency uses individualized blood pressure, urine, kidney-function, and blood tests, along with retinal exams. If a kidney transplant is needed, recurrence risk and preventive complement-blocking medicine depend on the CFH variant and other factors.

Reaching a period of stability or “remission” with Complement Factor H (CFH)-related disease is a major milestone, but it is not the end of the journey. Because your genetic “blueprints” still carry a susceptibility, long-term health requires a personalized strategy of ongoing monitoring [1][2].

Monitoring from Home and Clinic

The goal of long-term monitoring is to catch a “flare” based on clinician-defined thresholds before it causes permanent damage to your kidneys or eyes [3].

Your Home Toolkit

Daily schedules should be highly individualized by your doctor rather than prescribed broadly.

  • Blood Pressure: Tracking blood pressure is important, as increases can signal kidney stress.
  • Urine Checks: While you may use urine dipsticks at home, it is important to note they can produce false positives or negatives, and visual “bubbles” are not a reliable measure of proteinuria. Direct questions about “trace” or “2+” readings to your doctor rather than interpreting them alone [4].

Clinical Lab Tests

In the clinic, your nephrologist will monitor quantitative metrics, distinguishing aHUS tracking from C3G tracking:

  • Serum Creatinine and eGFR: These measure how well your kidneys are filtering waste [3].
  • Complement Levels: Tests for C3, CH50, and activation markers like sC5b-9 are used, but they do not consistently track clinical activity. Crucially, CH50 is intentionally low during C5 inhibition [5][6].
  • Hemolysis Markers: Blood tests like haptoglobin, LDH, and a platelet count check for the tiny blood clots characteristic of aHUS [3][7].

Protecting Your Vision

Because Factor H abnormalities can be associated with retinal issues, you may need a specialized eye doctor (an ophthalmologist) who understands retinal disease [8].

The focus of these exams is to look for drusen—yellowish deposits of metabolic waste—and signs of atrophy (thinning) or new, leaky blood vessels in the retina [8][9]. Your doctor may use:

  • Fundus Photography: High-resolution photos of the back of your eye.
  • OCT (Optical Coherence Tomography): A non-invasive scan that shows the individual layers of your retina in 3D, allowing for the detection of tiny changes [10][9].

The Path to Kidney Transplant

If CFH-related disease has led to kidney failure, a transplant may be considered. However, it requires a very specific plan because the susceptibility is still in your blood [11].

The Risk of Recurrence

In the past, many patients lost their new kidneys because the disease returned (recurred) almost immediately. Because the Factor H protein is made primarily in the liver, getting a new kidney does not fix the underlying genetic deficiency [12].

  • High Risk: Patients with specific CFH mutations have one of the highest risks for complement-mediated aHUS disease recurrence after a transplant [13][14].
  • Variable Risk: The risk of recurrence and the preventative strategies vary significantly between aHUS and C3G, and also depend heavily on your specific genotype, donor factors, and antibody status [15].

Prophylactic Protection

Specialized transplant centers often consider using prophylactic (preventative) C5 inhibitors—like eculizumab or ravulizumab—around the time of the transplant surgery for high-risk patients [16][11].

  • Prevention vs. Rescue: For appropriate high-risk aHUS patients, starting these medications before the transplant (prophylaxis) is generally more effective at saving the new kidney than waiting for the disease to return [16][17].
  • Individualized Support: While prolonged or lifelong therapy is often considered in high-risk situations, it must be individualized. Prophylactic eculizumab is not a universal mandate for every CFH-related disorder (particularly C3G), and decisions depend on local transplant expertise [2][18].

Survivorship means accepting a “new normal.” While the threat of a flare-up is present, modern monitoring and preventative treatments allow many patients to lead full, active lives [19]. Your best defense is a close partnership with a care team that understands the unique needs of your immune system.

Common questions in this guide

How is CFH deficiency monitored when the disease is stable?
Your care team may ask you to track blood pressure and sometimes urine at home, while clinic visits can include kidney-function tests, complement tests, platelet counts, and tests for red-cell breakdown. The schedule and thresholds for calling the team should be individualized because laboratory values do not always mirror disease activity.
Can I rely on home urine dipsticks to tell whether CFH disease is flaring?
Home dipsticks can provide useful information about blood or protein in the urine, but they can give false-positive or false-negative results. Do not use bubbles in the urine or an isolated trace or 2+ reading to diagnose a flare; share the result with your clinician and interpret it with other test results.
What eye monitoring is recommended for CFH deficiency?
An ophthalmologist with retinal expertise may use fundus photography and optical coherence tomography, or OCT, to examine the retina. These tests can help identify drusen, retinal thinning, and new leaky blood vessels and monitor changes over time.
Why are C3 and CH50 not enough to show whether CFH disease is active?
Complement tests such as C3, CH50, and sC5b-9 may be included in follow-up, but they do not consistently track clinical activity. CH50 is expected to be low during treatment with a C5 inhibitor, so your team must interpret it alongside kidney function and other blood tests.
Can CFH-related disease come back after a kidney transplant?
Yes. A new kidney does not correct the underlying CFH problem because Factor H is made mainly in the liver, and some CFH mutations carry a high risk of recurrence. The risk also depends on whether the condition is aHUS or C3G, your genotype, donor factors, and antibody status.
Will I need eculizumab or ravulizumab around a kidney transplant?
Specialized transplant teams may recommend preventive C5 inhibitor treatment, such as eculizumab or ravulizumab, before or around surgery for patients at high risk, particularly with aHUS. It is not automatically required for every CFH-related disorder, especially C3G, and the duration of treatment should be individualized.

Get notified when new evidence is published on complement factor H deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

    Goodship TH, Cook HT, Fakhouri F, et al.

    Kidney international 2017; (91(3)):539-551 doi:10.1016/j.kint.2016.10.005.

    PMID: 27989322
  2. 2

    Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

    Fakhouri F, Fila M, Provôt F, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.

    PMID: 27799617
  3. 3

    Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report.

    Yang H, Zhang J, Wu H, et al.

    Frontiers in immunology 2025; (16()):1542973 doi:10.3389/fimmu.2025.1542973.

    PMID: 40264782
  4. 4

    C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.

    Garg N, Zhang Y, Nicholson-Weller A, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(12)):2260-2265 doi:10.1093/ndt/gfx369.

    PMID: 29370420
  5. 5

    [Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].

    Yurova VA, Kozlovskaya NL, Bobrova LA, et al.

    Terapevticheskii arkhiv 2023; (95(6)):475-480 doi:10.26442/00403660.2023.06.202269.

    PMID: 38158966
  6. 6

    Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.

    Cammett TJ, Garlo K, Millman EE, et al.

    Molecular diagnosis & therapy 2023; (27(1)):61-74 doi:10.1007/s40291-022-00620-3.

    PMID: 36329366
  7. 7

    C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.

    Bajwa R, DePalma JA, Khan T, et al.

    Case reports in nephrology and dialysis 2018; (8(1)):25-34 doi:10.1159/000486848.

    PMID: 29594148
  8. 8

    Retinal disease in the C3 glomerulopathies and the risk of impaired vision.

    Savige J, Amos L, Ierino F, et al.

    Ophthalmic genetics 2016; (37(4)):369-376 doi:10.3109/13816810.2015.1101777.

    PMID: 26915021
  9. 9

    Simultaneous GA and CNV/MNV: incidence, characteristics, and treatments.

    Kataoka K, Gale R, Li X, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(5)):1197-1212 doi:10.1007/s00417-024-06721-5.

    PMID: 40229571
  10. 10

    Phenotypic Expression of CFH Rare Variants in Age-Related Macular Degeneration Patients in the Coimbra Eye Study.

    Farinha C, Barreto P, Coimbra R, et al.

    Investigative ophthalmology & visual science 2022; (63(9)):5 doi:10.1167/iovs.63.9.5.

    PMID: 35925583
  11. 11

    Thrombotic microangiopathy after kidney transplant: a mechanistic + therapeutic decision tree.

    Chutani A, Francis JM, Mahmoud H

    Current opinion in nephrology and hypertension 2026; doi:10.1097/MNH.0000000000001239.

    PMID: 42989633
  12. 12

    Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation.

    Kim S, Park E, Min SI, et al.

    Journal of Korean medical science 2018; (33(1)):e4 doi:10.3346/jkms.2018.33.e4.

    PMID: 29215813
  13. 13

    De Novo and Recurrent Thrombotic Microangiopathy After Renal Transplantation: Current Concepts in Management.

    Abbas F, Abbas SF

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2022; (20(6)):549-557 doi:10.6002/ect.2021.0069.

    PMID: 34546154
  14. 14

    Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation.

    Bouatou Y, Bacchi VF, Villard J, et al.

    Transplantation direct 2015; (1(2)):e9 doi:10.1097/TXD.0000000000000518.

    PMID: 27500215
  15. 15

    Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.

    Duineveld C, Bouwmeester RN, Wijnsma KL, et al.

    Kidney international reports 2023; (8(4)):715-726 doi:10.1016/j.ekir.2023.01.016.

    PMID: 37069997
  16. 16

    Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.

    Gonzalez Suarez ML, Thongprayoon C, Mao MA, et al.

    Journal of clinical medicine 2019; (8(7)) doi:10.3390/jcm8070919.

    PMID: 31252541
  17. 17

    Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

    Zuber J, Frimat M, Caillard S, et al.

    Journal of the American Society of Nephrology : JASN 2019; (30(12)):2449-2463 doi:10.1681/ASN.2019040331.

    PMID: 31575699
  18. 18

    Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.

    Acosta-Medina AA, Moyer AM, Go RS, et al.

    Blood advances 2023; (7(3)):340-350 doi:10.1182/bloodadvances.2021006416.

    PMID: 35533258
  19. 19

    Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

    Chaturvedi S, Dhaliwal N, Hussain S, et al.

    Blood advances 2021; (5(5)):1504-1512 doi:10.1182/bloodadvances.2020003175.

    PMID: 33683339

This page about long-term CFH deficiency monitoring and survivorship is for informational purposes only and does not constitute medical advice. Your nephrologist, ophthalmologist, and transplant team should tailor testing and treatment to your situation.

Guide contents complement factor H deficiency
Research & Literature
05 Treatment Strategies and Medical Management